January 8, 2018
Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment
Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
By Bill Snyder